Immunopharmacological characterization of a highly branched fungal (1-->3)-beta-D-glucan, OL-2, isolated from Omphalia lapidescens.
The immunopharmacological activities of a fungal (1-->3)-beta-D-glucan, OL-2, isolated from "Leiwan" Omphalia lapidescens were examined. Intraperitoneal (i.p.) administration of OL-2 to ICR mice induced a significant number of peritoneal exudate cells (PEC) and white blood cells over the period of a few days. Spleen cell numbers were also increased by i.p. administration of OL-2 at about a week. These changes reverted to the normal level within a month. Responses of spleen cells and bone marrow cells (BM) to colony stimulating factors (CSF) were augmented by OL-2 administration assessed by cell proliferation assay. Sera from OL-2 administered mice contained an increased concentration of colony stimulating activity. Gene expressions of interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha in the spleen were also increased. These results suggested the activation of hematopoietic responses, and would well relate to the incremental increase in PEC, white blood cell and spleen cell numbers. OL-2 also increased the serum concentration of fibronectin and complement component C-3. However, OL-2 did not show adjuvant activity to SRBC and antitumor activity against the solid form of Sarcoma 180 by i.p. administration. Yet, OL-2 did not interfere with the antitumor activity of SSG against the same tumor system. These facts suggested that OL-2 could enhance nonspecific host defense mechanisms by enhancing hematopoietic responses, but would not enhance or inhibit the specific immunity mediated by lymphocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
Ohno
N
N
Tokyo College of Pharmacy, Japan.
Saito
K
K
Nemoto
J
J
Kaneko
S
S
Adachi
Y
Y
Nishijima
M
M
Miyazaki
T
T
Yadomae
T
T
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000363:Agaricales / Q000737:chemistry*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D001483:Base Sequence; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003176:Complement C3 / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis; D005353:Fibronectins / Q000097:blood / Q000276:immunology; D005936:Glucans / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D007958:Leukocyte Count / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D008813:Mice, Inbred ICR; D008969:Molecular Sequence Data; D012333:RNA, Messenger / Q000096:biosynthesis; D012510:Sarcoma 180 / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D003176:Complement C3; D016207:Cytokines; D005353:Fibronectins; D005936:Glucans; D012333:RNA, Messenger; C074376:OL 2